Pfizer to temporarily reduce Covid-19 vaccine supplies to Europe

Pfizer / BioNTech vaccine.
Pfizer / BioNTech vaccine. / AFP
  • The pharmaceutical company has announced that the decrease in the number of shipments is due to the need to improve its production process

Pfizer / BioNTech, the consortium on which the bulk of the supply of coronavirus vaccines in the European Union currently rests, announced this Friday that as of next week there will be a delay in deliveries.

According to the statement from the companies, this delay is due to readjustments to allow laboratories to increase their production capacity.

"It is not clear how long exactly it will take for Pfizer to resume its maximum production capacity, which will go from 1,300 to two billion doses," the companies explained in a statement.

Pfizer, however, said that the “readjustment” will affect the deliveries of January and early February, but that it will mean a notable increase in the doses distributed at the end of February and March.

The Spanish Ministry of Health, according to sources from the department headed by Salvador Illa, still does not know to what extent these limitations will affect its current supply, which is set at about 350,000 vials per week.

But health sources said that it is very likely that the inoculation of new patients will have to be slowed down to allow for the injection of booster doses for people who have already been vaccinated.

In theory, Spain should have 60 million vials of the Pfizer vaccine during 2021.

Pfizer / BioNTech has also announced plans to accelerate the production and distribution of its vaccine involve "outsourcing" the manufacture of its compounds to other companies. The German company has already closed agreements with five other European plants and is negotiating production agreements with other companies.